OPNT News and Press, Opiant Pharmaceuticals Inc. From 10/21/21

SANTA MONICA, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report third quarter 2021 financial resul...

Biopharmaceuticals company Bristol Myers Squibb’s (BMY) strong clinical and operational performance and continued momentum across its product portfolio helped it generate robust revenue growth in its last reported quarter. But given that its stock price has dipped recently, is now an o...

Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) traded today at a new 52-week high of $25.90. This new high was reached on above average trading volume as 949,000 shares traded hands, while the average 30-day volume is approximately 56,000 shares. There is potential upside of 12.2% for shares ...

Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) traded today at a new 52-week high of $24.62. This new high was reached on above average trading volume as 949,000 shares traded hands, while the average 30-day volume is approximately 52,000 shares. Opiant Pharmaceuticals Inc is a specialty phar...

Today, we take our first in-depth look at Opiant Pharmaceuticals, a small biopharma concern targeting addiction. The company reported better-than-expected Q2 results and some recent trial results might have minimized the risk in the investment case around the stock. A full investm...

Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) traded today at a new 52-week high of $24.00. Approximately 949,000 shares have changed hands today, as compared to an average 30-day volume of 48,000 shares. Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. I...

Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) traded today at a new 52-week high of $22.31. Approximately 949,000 shares have changed hands today, as compared to an average 30-day volume of 46,000 shares. There is potential upside of 26.7% for shares of Opiant Pharmaceuticals Inc. based on a...

SANTA MONICA, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT) today announced that members of the company’s senior management team will participate in the following virtual investor conferences: H.C. Wainwr...

The pharmaceutical industry is expected to attract significant investor attention in the coming months as the demand for vaccines and therapies continues to soar with the resurgence of COVID-19 cases globally. This demand, coupled with an astonishing level of scientific advances for treating ...

Opiant Pharmaceuticals, Inc. (OPNT) Q2 2021 Earnings Conference Call August 05, 2021, 16:30 ET Company Participants Ben Atkins - VP, Communications & IR Roger Crystal - President, CEO & Director David O'Toole - CFO Conference Call Participants Carl Byrnes - Northland Capital Markets D...